Cleo Diagnostics Ltd (ASX:COV)

Cleo Diagnostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023
Other Revenue	0.21	0.21	-
Revenue	0.21	0.21	-
Gross Profit	0.21	0.21	-
Selling, General & Admin	1.18	1.1	1.37
Research & Development	2.09	2.57	0.25
Other Operating Expenses	0.08	0.12	0.04
Operating Expenses	3.41	3.85	1.7
Operating Income	-3.2	-3.64	-1.7
Interest Expense	-	-0.03	-0.11
Interest & Investment Income	0.36	0.36	-
Other Non Operating Income (Expenses)	-0.26	-0.45	0.08
Pretax Income	-3.1	-3.76	-1.73
Net Income	-3.1	-3.76	-1.73
Net Income to Common	-3.1	-3.76	-1.73
Shares Outstanding (Basic)	109	117	26
Shares Outstanding (Diluted)	109	117	26
Shares Change (YoY)	25.28%	346.76%	-
EPS (Basic)	-0.03	-0.03	-0.07
EPS (Diluted)	-0.03	-0.03	-0.07
Free Cash Flow	-2.8	-2.03	-0.72
Free Cash Flow Per Share	-0.03	-0.02	-0.03
Gross Margin	100.00%	100.00%	-
Operating Margin	-1517.31%	-1727.45%	-
Profit Margin	-1469.73%	-1783.22%	-
Free Cash Flow Margin	-1326.90%	-964.47%	-
EBITDA	-3.14	-3.58	-1.66
D&A For EBITDA	0.06	0.06	0.04
EBIT	-3.2	-3.64	-1.7

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.